3,741,918 Medline $MDLN Shares Sold by Bessemer Group Inc.

Medline logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Bessemer Group cut its Medline holdings by 66.2% in the third quarter, selling 3,741,918 shares and retaining 1,906,578 shares valued at about $66.2 million.
  • Analyst sentiment is mixed: 23 analysts rate the stock Buy, four Hold, and two Sell, for a consensus “Moderate Buy” rating and a $46.08 price target.
  • Medline reported quarterly earnings of $0.44 per share, beating the $0.32 consensus estimate, on revenue of $7.86 billion.
  • MarketBeat previews the top five stocks to own by December 1st.

Bessemer Group Inc. lowered its holdings in Medline (NASDAQ:MDLN - Free Report) by 66.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,906,578 shares of the company's stock after selling 3,741,918 shares during the quarter. Bessemer Group Inc. owned approximately 0.15% of Medline worth $66,158,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of MDLN. Janus Henderson Group PLC lifted its holdings in Medline by 8.4% during the first quarter. Janus Henderson Group PLC now owns 11,451,861 shares of the company's stock worth $506,546,000 after buying an additional 887,240 shares during the period. Banque Pictet & Cie SA raised its position in shares of Medline by 2.0% in the 3rd quarter. Banque Pictet & Cie SA now owns 7,455,089 shares of the company's stock worth $258,692,000 after acquiring an additional 142,939 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its position in shares of Medline by 233.3% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 5,000,000 shares of the company's stock worth $222,500,000 after acquiring an additional 3,500,000 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Medline by 30,255.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,700,425 shares of the company's stock worth $94,353,000 after purchasing an additional 2,691,529 shares during the last quarter. Finally, Unisphere Establishment boosted its position in Medline by 50.5% during the first quarter. Unisphere Establishment now owns 2,482,500 shares of the company's stock valued at $110,471,000 after purchasing an additional 832,500 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Mizuho reduced their target price on shares of Medline from $48.00 to $45.00 and set an "outperform" rating for the company in a report on Thursday, October 22nd. Zacks Research cut shares of Medline from a "hold" rating to a "strong sell" rating in a report on Tuesday, October 20th. Wells Fargo & Company cut their price objective on shares of Medline from $45.00 to $34.00 and set an "equal weight" rating on the stock in a research report on Tuesday, August 11th. Citigroup boosted their price objective on shares of Medline from $45.00 to $47.00 and gave the stock a "buy" rating in a research note on Thursday, November 5th. Finally, Truist Financial decreased their target price on shares of Medline from $56.00 to $47.00 and set a "buy" rating for the company in a research report on Thursday, August 6th. Twenty-three investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $46.08.

Check Out Our Latest Stock Analysis on MDLN

Insider Buying and Selling

In other Medline news, major shareholder Private Ltd Gic sold 2,088,987 shares of the stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $35.05, for a total transaction of $73,218,994.35. Following the sale, the insider directly owned 16,453,806 shares of the company's stock, valued at approximately $576,705,900.30. This trade represents a 11.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 6,348,676 shares of company stock valued at $224,525,137 over the last 90 days. 0.81% of the stock is currently owned by corporate insiders.

Medline Price Performance

NASDAQ MDLN opened at $39.17 on Tuesday. The company has a market cap of $51.52 billion and a price-to-earnings ratio of 89.02. The company has a debt-to-equity ratio of 0.65, a current ratio of 4.04 and a quick ratio of 2.51. The stock's fifty day moving average price is $35.33 and its 200 day moving average price is $39.34. Medline has a 1 year low of $31.37 and a 1 year high of $50.88.

Medline (NASDAQ:MDLN - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.32 by $0.12. Medline had a return on equity of 8.21% and a net margin of 1.84%. The business had revenue of $7.86 billion for the quarter. As a group, equities research analysts forecast that Medline will post 1.58 earnings per share for the current year.

Medline Profile

(Free Report)

Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.

Further Reading

Want to see what other hedge funds are holding MDLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medline (NASDAQ:MDLN - Free Report).

Institutional Ownership by Quarter for Medline (NASDAQ:MDLN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Medline Right Now?

Before you consider Medline, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medline wasn't on the list.

While Medline currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines